ErbB Ligands in Angiogenesis

摘要: The formation of new blood vessels, i.e. angiogenesis, is an important phenomenon during normal development and wound repair, as well various pathological processes, such tumor growth metastasis. Specific factors regulate angiogenesis by modulating the different cellular functions endothelial cells (EC), periendothelial cells, pericytes (PC) smooth muscle (SMC), which interact with ECs in a paracrine manner. ErbB receptors form subgroup transmembrane receptor tyrosine kinases that epidermal factor (EGF) family. behaviour variety cell types. Cancer drugs target (EGFR, ErbB1) or ErbB2 have been approved for clinical use. It has speculated part antitumor activity inhibitor compounds result from antiangiogenic mechanism. results presented here indicate role endothelial-derived EGF-like heparin binding (HB-EGF) neuregulin-1 (NRG-1) regulation angiogenesis. HB-EGF, EGFR are shown to mediate interaction between SMCs vitro, gefitinib, kinase activity, suppresses recruitment PCs/SMCs vivo. NRG-1 EC vitro vivo indirect mechanisms involving vascular factor-A (VEGF-A) VEGF receptor-2 (VEGFR-2). Furthermore, demonstrated bone marrow-derived perivascular neovascularization These signaling involved processes vessel formation. This study gives information about ligands vasculogenesis gefitinib affect growth.